Clinical outcomes and prognostic factors for patients with high‐risk gastrointestinal stromal tumors treated with 3‐year adjuvant imatinib
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34157
Abstract: Three years of adjuvant imatinib is the current standard for patients with high‐risk gastrointestinal stromal tumors (GIST). We aimed to investigate the safety and efficacy profiles of 3‐year imatinib, focusing on the prognostic value of… read more here.
Keywords: year; adjuvant imatinib; patients high; high risk ... See more keywords
Comparison of Prognosis Between Microscopically Positive and Negative Surgical Margins for Primary Gastrointestinal Stromal Tumors: A Systematic Review and Meta-Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.679115
Abstract: Background This meta-analysis aimed to determine the prognostic impact of microscopically positive margins (R1) on primary gastrointestinal stromal tumors. Methods A literature search was performed using PubMed, Embase, Web of Science, and Cochrane Library for… read more here.
Keywords: meta analysis; adjuvant imatinib; reference; margins primary ... See more keywords